Transcode Therapeutics

RNAZ · NASDAQ

$1.68−$0.02 (−1.18%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.70

About RNAZ

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees: 7
Headquarters: Boston, Massachusetts
Listed: Apr 28, 2021
Sector: Health Care
Industry: Biotechnology
Website: transcodetherapeutics.com

Leadership

Transcode Therapeutics executives
Name	Title	Since	Age
Philippe Calais	—	2021	66
Thomas Fitzgerald	—	2018	74
Daniel Vlock	—	—	—
Elizabeth Czerepak	—	—	—
Erik Manting	—	—	54
Magda Marquet	—	—	66
Jack Stover	—	—	69

Similar companies

Companies in the same industry as Transcode Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.